Company Filing History:

12 out of 22

Xention Limited

patents

Years Active: 2006-2016

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9447033 - Potassium channel blockers (2016-09-20),

2. 9290511 - Thieno-pyrimidines, useful as potassium channel inhibitors (2016-03-22),

3. 9216992 - Thieno[3,2-c]pyridine potassium channel inhibitors (2015-12-22),

4. 9073834 - Potassium channel blockers (2015-07-07),

5. 8673901 - Potassium channel blockers (2014-03-18),

6. 8426442 - Compounds (2013-04-23),

7. 8399481 - Compounds (2013-03-19),

8. 8372840 - Potassium channel blockers (2013-02-12),

9. 8258138 - Potassium channel blockers (2012-09-04),

10. 8193215 - Thieno[2 3-b]pyridines as potassium channel inhibitors (2012-06-05),

11. 8022076 - Substituted thieno[2,3-d]pyrimidines as potassium channel inhibitors (2011-09-20),

12. 7576212 - Thieno[2,3-B] pyridines as potassium channel inhibitors (2009-08-18),

13. 7456187 - Furanopyrimidine compounds as potassium ion channel inhibitors (2008-11-25),

14. 7112572 - Multivalent metal salts of boronic acids (2006-09-26),

Title: The Innovative Journey of David John Madge

Introduction:

David John Madge, a distinguished inventor hailing from Cambridgeshire, Great Britain, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 14 patents to his name, Madge's work focuses on potassium channel blockers and thieno-pyrimidines for therapeutic use.

Latest Patents:

Madge's latest patents include the development of potassium channel blockers, which are compounds designed to inhibit potassium ion channels effectively. These compounds hold potential in the treatment of various diseases mediated by specific potassium ion channel subunits. Additionally, his work on thieno-pyrimidines showcases their utility as potassium channel inhibitors in pharmaceutical compositions for therapeutic applications.

Career Highlights:

Throughout his career, Madge has been associated with esteemed companies in the pharmaceutical industry. Notably, he has lent his expertise to Xention Limited and Trigen GmbH. His innovative research and patent applications have propelled the advancement of drug discovery and development in these organizations.

Collaborations:

In his pursuit of innovation, Madge has collaborated with accomplished professionals in the field. Among his notable coworkers are John Ford and Derek Edward John, who have contributed to the collective efforts in developing novel pharmaceutical compounds and formulations.

Conclusion:

David John Madge's dedication to scientific innovation and patenting has established him as a prominent figure in the pharmaceutical landscape. His patents on potassium channel blockers and thieno-pyrimidines reflect his commitment to advancing therapeutic solutions for complex medical conditions. Through his collaborations and career milestones, Madge continues to shape the future of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.